| Literature DB >> 33493427 |
Shuhei Kanagaki1,2, Takahiro Suezawa1,2, Keita Moriguchi1,2, Kazuhisa Nakao2, Masayasu Toyomoto1,3, Yuki Yamamoto1, Koji Murakami2, Masatoshi Hagiwara3, Shimpei Gotoh1.
Abstract
Alveolar epithelial type II (AT2) cells secrete pulmonary surfactant via lamellar bodies (LBs). Abnormalities in LBs are associated with pulmonary disorders, including fibrosis. However, high-content screening (HCS) for LB abnormalities is limited by the lack of understanding of AT2 cell functions. In the present study, we have developed LB cells harboring LB-like organelles that secrete surfactant proteins. These cells were more similar to AT2 cells than to parental A549 cells. LB cells recapitulated amiodarone (AMD)-induced LB enlargement, similar to AT2 cells of patients exposed to AMD. To reverse AMD-induced LB abnormalities, we performed HCS of approved drugs and identified 2-hydroxypropyl-β-cyclodextrin (HPβCD), a cyclic oligosaccharide, as a potential therapeutic agent. A transcriptome analysis revealed that HPβCD modulates lipid homeostasis. In addition, HPβCD inhibited AMD-induced LB abnormalities in human induced pluripotent stem cell-derived AT2 cells. Our results demonstrate that LB cells are useful for HCS and suggest that HPβCD is a candidate therapeutic agent for AMD-induced interstitial pneumonia.Entities:
Keywords: 2-hydroxypropyl-β-cyclodextrin; alveolar epithelial type 2 cells; amiodarone; high-content screening; lamellar bodies
Mesh:
Substances:
Year: 2021 PMID: 33493427 DOI: 10.1165/rcmb.2020-0119OC
Source DB: PubMed Journal: Am J Respir Cell Mol Biol ISSN: 1044-1549 Impact factor: 6.914